BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 30, 2026
Home » Blogs » BioWorld MedTech Perspectives » First-to-file vs. first-to-invent: Which patent system would be better for the U.S.?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / Patents

First-to-file vs. first-to-invent: Which patent system would be better for the U.S.?

March 4, 2011
By Holland Johnson

Patent reform legislation has been in the news quite a bit the past few weeks in the U.S., with both chambers of Congress working on legislation that could affect the way patents are currently registered.

The U.S. patent system is currently based on a first-to-invent doctrine, which means that the inventor who first conceived of the invention and then reduced it to practice by filing a patent application is considered the first inventor and is entitled to patent protection. Every other country in the world, except the Phillipines, has a patent system based on the first-to-file doctrine, in which the patent is granted to the inventor who is the first to file a patent application, regardless of the date of invention.

Last week, Sen. Diane Feinstein (D-California) proposed an amendment to the patent reform bill (S. 23) to strike the first-to-file provision. Feinstein, whose amendment was soundly defeated, said that she believed that first-to-file “would be severely harmful to innovation and especially burdensome on small inventors.” She added that, “under first-to-invent, we have been the world’s leader in innovation, and the first-to-file countries have been playing catch-up.”

Sen. Orrin Hatch (R-Utah), one of the architects of patent reform, rebutted Feinstein’s claims that the current system is better for the small inventor than first-to-file. He said that under the current system, “if there’s a dispute, it costs applicants an average of $500,000 in legal fees to prove they were the first to invent,” a sum he said would fall to $100 under first-to-file.

Sen. John Kyl (R-Arizona), added that first-to-file has “been the subject of debate for about 20 years” and was thoroughly vetted in both chambers of Congress in previous attempts at reform. “This provision . . . is supported by all three patent organizations,” including the American Bar Association (Washington), “and very importantly, has the support of independent inventors.”

Some opponents of the first-to-file system also raise a constitutional argument, citing Article I, Section 8 of the Constitution which says: "The Congress shall have power...To promote the progress of science and useful arts, by securing for limited times to authors and inventors the exclusive right to their respective writings and discoveries."

So for a first-to-file system to be constitutional would there need to be a change in the way an inventor is constitutionally defined?

Which patent filing system do you prefer for the U.S. and why?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 27, 2026.
  • Art concept for Parkinson's disease

    Emerging therapeutic strategies for Parkinson’s at ADPD 2026

    BioWorld
    Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
  • Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

    Small-molecule TREM2 agonist advances to treat Alzheimer’s

    BioWorld Science
    Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
  • Vials, syringes, and pills

    With improved technologies, biomarkers, failed drugs may come into their own

    BioWorld
    At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 24, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing